As the global economy mends, the 2021 growth of Omnicef will have significant change from previous year. According to our (LP Information) latest study, the global Omnicef market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Omnicef market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Omnicef market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Omnicef market, reaching US$ million by the year 2028. As for the Europe Omnicef landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Omnicef players cover Astellas Pharma, Sandoz (Novartis), TEVA, and Aurobindo, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Omnicef market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Tablets
Capsule
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Infections In The Ear
Infections In The Sinus
Infections In The Throat
Infections In The Lungs
Infections In The Skin
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Astellas Pharma
Sandoz (Novartis)
TEVA
Aurobindo
ORCHID PHARMA
LUPIN
YONGNING PHARMA
CSPC
GENCOM
QILU ANTIBIOTICS
UNION CHEMPHARMA
HANSOH
LUKANG
Tianjin Huajin Pharmaceutical
Tianjin Central Pharmaceutical
Guangdong Bozhou Pharmaceutical
Jiangsu Yabang Qiangsheng Pharmaceutical
Hainan Rizhongtian Pharmaceutical
Heilongjiang Zhaodong Huafu Pharmaceutical
Tianjin Pharmaceutical Group Jinkang Pharmaceutical
Jiangsu Haosen Pharmaceutical Group
Zhejiang Jutai Pharmaceutical